Please login to the form below

Not currently logged in
Email:
Password:

PD-L1 inhibitors

This page shows the latest PD-L1 inhibitors news and features for those working in and with pharma, biotech and healthcare.

Lilly buys Armo for $1.6bn to bolster immuno-oncology pipeline

Armo has said it thinks that the drug will increase the activity of PD-1/PD-L1 checkpoint inhibitors. ... Lilly already has a PD-L1 drug in phase I testing, while Armo also has a PD-1 antibody heading for clinical trials as well as recombinant IL-12 and

Latest news

  • BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

    Meanwhile another study of epacadostat with AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) will also not go ahead. ... 1/PD-L1 inhibitors, but the drug has been firmly relegated to speculative status.

  • Merck’s Keytruda scores in frontline lung cancer yet again Merck’s Keytruda scores in frontline lung cancer yet again

    NSCLC, including those with both squamous and non-squamous types and a full range of PD-L1 expression levels from 1% and above. ... are both hoping to find a role for combinations pairing PD-1/PD-L1 inhibitors with CTLA4 inhibitors.

  • Incyte/Merck trial failure bodes ill for IDO class Incyte/Merck trial failure bodes ill for IDO class

    BMS is also partnered with Incyte on a trial of its PD-1 inhibitor Opdivo (nivolumab) with epacadostat, as is AstraZeneca with its PD-L1 blocker Imfinzi (durvalumab), so the blow ... That means for now, PD1/PD-L1 inhibitors as monotherapy, or combined

  • AZ pushes back data read-out from MYSTIC lung cancer trial AZ pushes back data read-out from MYSTIC lung cancer trial

    questions about the validity of combining PD-1/PD-L1 and CTLA4 inhibitors in these patients. ... TMB differs from the usual PD-L1 expression biomarker used in trials of PD-1/PD-L1 inhibitors and has been proposed as a superior option for immuno-oncology

  • BMS gets OK for monthly Opdivo dosing BMS gets OK for monthly Opdivo dosing

    cancer. It is competing in the marketplace with two other PD-1 inhibitors - Merck &Co/MSD’s Keytruda (pembrolizumab) and Roche’s Tecentriq (atezolizumab) - as well as PD-L1 inhibitors Imfinzi ... The company is maintaining its lead in the PD-1/PD-L1

More from news
Approximately 1 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Companies are looking to pair their PD-1/PD-L1 checkpoint inhibitors with a variety of other agents to stimulate a more robust anticancer immune response, ”says Xuan.

  • European venture funding for the life science sector European venture funding for the life science sector

    is likely to accelerate interest - the sheer number of combination therapies and PD-1/PD-L1 inhibitors could result in a commoditisation of this area that could threaten returns for venture

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    170. Checkpoint Therapeutics / TG. Licence and collaboration. Human anti-PD-L1 and anti-GITR antibody preclinical programmes for haematological cancers. ... CAR-T and checkpoint inhibitors PD-1 and PD-L1. 110. Transtech / Calithera.

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    PD-L1 and PD-1 CP inhibitors. Co-development and co-marketing alliance. 2, 850. ... FPA008 mAb inhibits (CSF1R) to be combined with nivolumab (PD-1 check-point inhibitor).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics